Bio-Matrix Scientific BMSN Receives Certificate of Compliance for Class 10,000 Processing Laboratory
Bio-Matrix Scientific Receives Certificate of Compliance for Class 10,000 Processing Laboratory
Nov 16 2006
Bio-Matrix Scientific Group Inc. (OTCBB:BMSN), a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced today it has received its Certificate of Compliance for the new Stem Cell Class 10,000 Processing Laboratory. The certificate has been granted by the Controlled Environmental Regulatory Testing Services (CERTS), which conducts ISO certification testing.
Bio-Matrix Scientific has completed the calibration and certification of the class 10,000 clean room and has received the ISO 14644 class 7 certificate of compliance. Bio-Matrix's stem cell processing laboratory now meets Federal Air Control Regulations to operate as a Class 10,000 Clean Room.
Bio-Matrix intends to utilize state-of-the art closed processing systems to harvest stem cells in its cord blood division by obtaining stem cells from fat tissue, which is a new dimension of stem cell banking. This processing system requires several procedures that must be carried out under strictly controlled environments to minimize the risk of microbial contamination.
Bio-Matrix Chairman & CEO David Koos stated, "This certificate of compliance, which forms part of our comprehensive cGMP (good manufacturing practices) and cGTP (good tissue practices) systems, will assure our customers that their stem cells are processed and stored under safe, controlled environments."
Bio-Matrix's new 15,000-sq-ft, state-of-the-art laboratory, located in the heart of the San Diego biotechnology corridor, will house Bio-Matrix's secure Cryogenic Stem Cell Bank; three research laboratories; an aseptic cellular/tissue class 10,000/100 processing laboratory; and hematology, microbiology and flow cytometry laboratories.
This press release is available on the company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to BMSN@agoracom.com, where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.
About Bio-Matrix Scientific Group Inc.
Bio-Matrix Scientific Group Inc. (www.BMSNonline.com) is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.
The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.
DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Nov 16 2006
Bio-Matrix Scientific Group Inc. (OTCBB:BMSN), a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced today it has received its Certificate of Compliance for the new Stem Cell Class 10,000 Processing Laboratory. The certificate has been granted by the Controlled Environmental Regulatory Testing Services (CERTS), which conducts ISO certification testing.
Bio-Matrix Scientific has completed the calibration and certification of the class 10,000 clean room and has received the ISO 14644 class 7 certificate of compliance. Bio-Matrix's stem cell processing laboratory now meets Federal Air Control Regulations to operate as a Class 10,000 Clean Room.
Bio-Matrix intends to utilize state-of-the art closed processing systems to harvest stem cells in its cord blood division by obtaining stem cells from fat tissue, which is a new dimension of stem cell banking. This processing system requires several procedures that must be carried out under strictly controlled environments to minimize the risk of microbial contamination.
Bio-Matrix Chairman & CEO David Koos stated, "This certificate of compliance, which forms part of our comprehensive cGMP (good manufacturing practices) and cGTP (good tissue practices) systems, will assure our customers that their stem cells are processed and stored under safe, controlled environments."
Bio-Matrix's new 15,000-sq-ft, state-of-the-art laboratory, located in the heart of the San Diego biotechnology corridor, will house Bio-Matrix's secure Cryogenic Stem Cell Bank; three research laboratories; an aseptic cellular/tissue class 10,000/100 processing laboratory; and hematology, microbiology and flow cytometry laboratories.
This press release is available on the company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to BMSN@agoracom.com, where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.
About Bio-Matrix Scientific Group Inc.
Bio-Matrix Scientific Group Inc. (www.BMSNonline.com) is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.
The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.
DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
posted by Famous Quotations - Bio-Matrix Scientific BMSN Receives Certificate of Compliance for Class 10,000 Processing Laboratory
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home